Background
Outcomes of patients with CLD undergoing transcatheter aortic valve replacement (TAVR) have not been systematically examined.
Methods
All patients who underwent TAVR in the PARTNER (Placement of AoRTic TraNscathetER Valve) trial, including the continued access registry (n ¼ 2,553; 1,108 with CLD), were evaluated according to CLD clinical severity. Additionally, outcomes of CLD patients included in the randomization arms of the PARTNER trial were compared: Cohort A patients (high-risk operable) treated by either TAVR (n ¼ 149) or surgical aortic valve replacement (SAVR); (n ¼ 138); and Cohort B patients (inoperable) treated by either TAVR (n ¼ 72) or standard therapy only (n ¼ 95).
Results
Among all TAVR-treated patients, at 1-year follow-up, patients with CLD had higher mortality than those without it (23.4% vs. 19 .6%, p ¼ 0.02). Baseline characteristics of CLD patients who underwent TAVR were similar to respective controls. In Cohort A, 2-year all-cause death rates were similar (TAVR 35.2% and SAVR 33.6%, p ¼ 0.92), whereas in Cohort B, the death rate was lower after TAVR (52.0% vs. 69.6% after standard therapy only, p ¼ 0.04). Independent predictors for mortality in CLD patients undergoing TAVR included poor mobility (6-min walk test <50 m; hazard ratio: 1.67, p ¼ 0.0009) and oxygen-dependency (hazard ratio: 1.44, p ¼ 0.02). Although CLD patients undergoing TAVR have worse outcomes than patients without CLD, TAVR is better in these patients than standard therapy and is similar to SAVR.
Conclusions
Although patients with CLD undergoing TAVR had worse outcomes than patients without CLD, TAVR performed better in these patients than standard therapy and was similar to SAVR. However, CLD patients who were either poorly mobile or oxygen-dependent had poor outcomes. Chronic lung disease (CLD) is common in patients with severe aortic stenosis (AS) (1) . Because lung disease is considered a risk for mortality and morbidity after surgical aortic valve replacement (SAVR) (2) , many patients with combined AS and CLD are referred for the less invasive transcatheter approach. The incidence of CLD in large transcatheter aortic valve replacement (TAVR) registries is 21% to 43% (3) (4) (5) (6) (7) (8) (9) (10) , while lung disease is suggested to be a predictor for lower survival after TAVR (10) (11) (12) . TAVR is superior to medical treatment in patients considered unsuitable for conventional surgery and is associated with similar long-term results in surgical high-risk patients when compared with SAVR (5, 6) . However, the outcome of patients with CLD undergoing TAVR has not been systematically studied and no comparison has been made between TAVR and alternative treatment strategies in CLD patients.
The current study has 2 main objectives: 1) to evaluate CLD impact on clinical outcomes following TAVR, or standard therapy; and 2) to identify predictors for poor outcome following TAVR in patients with CLD. Patients from both the randomized controlled trial (RCT) and nonrandomized continued access (NRCA) registry of the PARTNER (Placement of AoRTic TraNscathetER Valve) trial were included in the analysis.
Methods
Study design. The design and initial results of the PARTNER trial have been previously published (5, 6, 13, 14) . Briefly, RCT enrolled patients with severe symptomatic AS who were either high risk for surgical AVR (Cohort A) or were deemed inoperable (Cohort B). Patients in the high-risk arm were randomized between surgery and TAVR via the transfemoral or transapical approach depending on transfemoral access suitability. Patients in the inoperable arm were randomized between standard therapy or transfemoral TAVR if vascular access was adequate.
Following completion of the RCT, an NRCA protocol allowed treatment of both Cohort A and Cohort B patients with TAVR. Inclusion/exclusion criteria, data collection, and monitoring were the same in both the NRCA and RCT; core laboratories for data analysis likewise remained unchanged. All patients in both the NRCA and RCT were presented and adjudicated as appropriate candidates during conference calls with the executive committee and other investigators. These presentations included patients' baseline characteristics as well as data on lung disease and its severity, including pulmonary function test results and data on oxygen dependency. For each patient included in the PARTNER trial, the Society of Thoracic Surgeons (STS) score was calculated. Patients were defined and stratified accordingly with regard to lung disease severity: none; mild: 1-s forced expiratory volume (FEV1) 60% to 75% of predicted, and/or on chronic inhaled or oral bronchodilator therapy; moderate: FEV1 50% to 59% of predicted, and/or on chronic steroid therapy aimed at lung disease; and severe: FEV1 <50% predicted, and/or room air partial pressure of O 2 <60 mm Hg or room air partial pressure of CO 2 >50 mm Hg. A baseline 6-min walk test (6MWT) was performed according to the American Thoracic Society guidelines (15) . Study endpoints were reported according to Valve Academic Research Consortium definitions (16) . All adverse events were adjudicated by an independent clinical events committee. Independent core laboratories analyzed all echocardiograms and electrocardiograms. All data were sent for analysis to an independent academic biostatistics group. The PARTNER study was approved by the institutional review board at each participating site, and all patients provided written informed consent. Patient populations. For the purpose of the present study, 2 different analyses were performed using subsets of patients from the PARTNER trial. In order to assess the effect of CLD on outcomes following TAVR or standard therapy, a population of CLD patients from the randomized arm of the PARTNER trial was analyzed (Fig. 1A) . In order to assess the impact of CLD on outcomes following TAVR, all patients undergoing TAVR in either the RCT or NRCA were stratified by disease clinical severity and analyzed (Fig. 1B) (Fig. 1A) . In these patients, comparison of treatment strategies between TAVR and control was performed: TAVR versus SAVR in Cohort A patients and TAVR versus standard therapy in Cohort B patients. Study endpoints included 30-day rates of all-cause death, cardiovascular death, major stroke, major vascular complication, major bleeding, and acute kidney injury. One-and 2-year rates of all-cause death, cardiovascular death, repeat hospitalization, and the composite of death or repeat hospitalization were also collected.
TAVR POPULATION. All patients who underwent TAVR in either the RCT or the NRCA were pooled (n ¼ 2,553) and stratified according to presence of CLD: patients without CLD (n ¼ 1,445) were compared to those with CLD (n ¼ 1,108). CLD patients were further divided into non-oxygen-dependent (n ¼ 836) and oxygen-dependent (n ¼ 272) (Fig. 1B) . Baseline characteristics were compared between patients with and without CLD, as well as between non-oxygen-dependent and oxygen-dependent CLD patients. Study endpoints included 30-day and 1-year New York Heart Association (NYHA) functional class, all-cause death, cardiovascular death, repeat hospitalization, and combined death or repeat hospitalization. In the group of CLD patients that underwent TAVR, independent correlates for 1-year death were evaluated. Statistical analysis. All analyses were performed with data from the as-treated patients in the 2 patient populations studied: CLD patients included in the randomization arms; and patients who underwent TAVR in either the RCT arms or in the NRCA. NRCA patients were not included in the evaluation of the CLD population between TAVR and control in order to keep these groups as closely matched as possible and to maintain the integrity of randomization. Continuous variables are summarized as mean AE SD or as medians and quartiles, as appropriate, and were compared using Student's t test or Mann-Whitney rank sum test accordingly. Categorical variables were compared by the chi-square or the Fisher exact test. Survival curves for timeto-event variables were constructed using Kaplan-Meier estimates, while comparisons relied on the log-rank test. Outcomes were compared for up to 2 years in an analysis that included only patients from the RCT and up to 1 year when patients from NRCA were included. Cox multivariable regression analysis was performed to identify independent correlates for 1-year survival in CLD patients who underwent TAVR. The multivariable model was built by selecting baseline variables of clinical interest and/or those that satisfied the entry criterion of p < 0.05 in a univariate analysis: patient age, sex, body mass index (BMI), STS score, renal failure, liver disease, peripheral vascular disease, diabetes mellitus, pulmonary artery pressure, aortic valve gradient, 6MWT, and oxygen dependency (vs. non-oxygen dependency). A 2-sided alpha level of 0.05 was used for all superiority testing. All statistical analyses were performed using SAS software, version 9.2 (SAS Institute, Cary, North Carolina).
Results

CLD population. TAVR VERSUS MEDICAL THERAPY.
CLD patients included in the inoperable arm (Cohort B) were treated by either transfemoral TAVR (n ¼ 72) or by standard therapy (n ¼ 95) (Fig. 1A) . Baseline characteristics were similar between groups ( Table 1) . The rate of all-cause death in inoperable CLD patients undergoing TAVR was 12.5% at 30 days (Table 2) After 2-year follow-up, all-cause death was lower in CLD patients undergoing TAVR versus medical therapy (52.0% vs. 69.6%, p ¼ 0.04) ( Fig. 2A) . Similarly, repeat hospitalization and the composite of death or repeat hospitalization were lower in the TAVR group (Fig. 2B) .
TAVR VERSUS SAVR. CLD patients included in the high-risk arm (Cohort A) were treated by either TAVR (n ¼ 149; pulmonary artery pressure, NYHA functional class IV, peripheral vascular disease, cerebrovascular disease, and lower permanent pacemaker implantation (Table 3) . At 1-year follow-up, CLD patients had a higher mortality rate than did patients without CLD (23.4% vs. 19.6%, p ¼ 0.02) and a higher rate of combined mortality or repeat hospitalization Fig. 3 ). Compared to non-oxygen-dependent CLD, those who were oxygen dependent were younger, were more often female, and had higher pulmonary artery pressure and NYHA functional class IV rates (Table 3) . Additionally, oxygen-dependent CLD patients had lower logistic EuroSCOREs and lower rates of coronary artery disease, previous bypass surgery, peripheral vascular disease, and permanent pacemaker. At 1-year follow-up, oxygen-dependent CLD patients had a higher mortality rate compared to those with non-oxygen dependent CLD (29.7% vs. 21.4%, p ¼ 0.004) and a higher rate of the combined endpoint of death or repeat hospitalization (42.5% vs. 32.3%, p ¼ 0.002) ( Table 4 ). The functional status of patients after TAVR was compared according to CLD clinical severity at baseline. Patients were divided into 3 groups: no CLD, non-oxygendependent CLD, and oxygen-dependent CLD (Fig. 4) . At baseline, 30 days and 1 year of follow-up, these 3 groups differed significantly: patients without CLD had the best functional class (Fig. 4) . CLD patients who were oxygen dependent had worse functional status than those in the other groups, which was manifested by higher rates of death or poor functional status (NYHA functional class III/IV) at both 30 days (45.1%) and 1 year (49.6%; p <0.0001 for both) (Fig. 4) .
The following baseline parameters were identified in CLD patients undergoing TAVR as independent predictors for 1-year all-cause mortality: short 6MWT, oxygen dependency, renal disease, low BMI, higher mean pulmonary artery pressure, and higher aortic valve gradient (Table 5 ). Baseline 6MWT in CLD patients undergoing TAVR was negatively correlated with both 1-year all-cause mortality and 1-year noncardiovascular mortality (p ¼ 0.02, p < 0.001, respectively). CLD patients with poor baseline mobility (6MWT <50 m) had a 4.9Â higher rate of noncardiovascular death during the first year after the procedure (20.9% vs. 4.3% in those with 6MWT >200 m). In 70.4% of patients with poor mobility who died during the first year after TAVR, the cause of death was noncardiovascular; 68.8% of patients who died from respiratory insufficiency during that 1-year period had CLD at baseline. Pulmonary hypertension severity in CLD patients undergoing TAVR was correlated at 1 year with both all-cause mortality and cardiovascular mortality (p ¼ 0.006, p ¼ 0.04, respectively).
A score for predicting all-cause death in CLD patients undergoing TAVR included the previous independent parameters. The PBOSS score (scale 0 to 5 points) includes Figure 5 illustrates the trend of 1-year all-cause death in CLD patients undergoing TAVR according to the PBOSS score (p < 0.001).
Discussion
TAVR is associated with significant clinical improvements in high-risk severe AS patients (17) (18) (19) . However, little was known about whether severe AS patients with CLD experience a similar improvement following the procedure. The current trial reached the following findings: 1) clinical improvement after TAVR in the general population of CLD patients did not differ significantly from patients without CLD; and 2) TAVR was superior to medical therapy in patients considered inoperable and had similar clinical outcomes when compared to SAVR in operable high-risk patients. However, 2 subgroups of CLD patients had relatively poor outcomes after TAVR: oxygen-dependent CLD patients, only half were alive with good functional status at 1-year follow-up; and CLD patients with poor mobility at baseline. Relatively immobile CLD patients had higher rates of death after TAVR, mostly secondary to noncardiovascular etiologies. Clinical improvement of CLD patients after aortic valve implantation. CLD is traditionally considered a risk factor for mortality and significant morbidity after cardiac surgery and it is suggested that many CLD patients do not improve clinically after SAVR (20) (21) (22) . Nevertheless, several studies suggest that in the current TAVR era, CLD patients referred for SAVR improve equally after the procedure as do patients without CLD (23, 24) . Similarly, there is no consensus regarding clinical improvement of CLD patients after TAVR; and lung disease is a common cause for deferring interventions (25, 26) . Several trials have suggested that baseline CLD is a predictor for mortality after TAVR (9-12) and pulmonary complications have emerged as a common etiology for noncardiac cause of death in patients undergoing TAVR (27) . CLD was also found to be a predictor for acute kidney injury and stroke after TAVR (28, 29) . Nevertheless, several large trials did not find CLD to be an independent predictor for mortality after TAVR. (4, 14, 30) . According to the current analysis, high-risk CLD patients with severe AS improve after TAVR similarly to those without CLD. Additionally, the current analysis revealed that the correlates for 1-year mortality in CLD patients after TAVR are different than those seen in the general population of patients undergoing TAVR (14) , and include short 6MWT, oxygen dependency, high pulmonary artery pressure, renal disease, and low BMI. In the TAVR population from the PARTNER trial, it should be noted that although lung disease patients were on average 3.1 years younger than those without CLD, their STS scores were significantly higher. Poor mobility of CLD patients. Poor exercise capacity of CLD patients is considered a significant marker for increased mortality, a stronger marker than the degree of airway obstruction (31) (32) (33) . 6MWT, when performed before several interventions, was used to identify patients at high risk for post-operative complications (34) (35) (36) . Gait speed was also found to be a strong independent correlate for mortality in patients undergoing cardiac surgery (37) . In severe AS patients, a poor 6MWT was found to be a marker for long-term mortality in patients with low-flow low-gradient AS and in those undergoing SAVR (38, 39) . The 6MWT was also examined in patients undergoing TAVR as a tool to assess clinical improvement (19, 40) . Our study reveals that a poor baseline 6MWT result in a CLD patient is associated with increased mortality after TAVR. Specifically, there is a significant correlation between 6MWT distance at baseline and noncardiovascular death at 1 year. The 6MWT should be further examined in the general population of patients undergoing TAVR as a marker for survival after the procedure. Frail, immobile patients may be considered for medical therapy only. TAVR and futility. Although TAVR improves quality of life and is cost effective (17, 41) in the general population of high-risk AS patients, there is a sizeable group of patients in whom clinical status does not improve after a seemingly successful TAVR procedure (4) (5) (6) 9) . It is conceivable that in some severe AS patients with numerous comorbidities, mechanical correction of their valve pathology will not result in improvement of their well-being; for them, TAVR is medically futile (42) . Several studies have attempted to define frailty as a marker for high surgical risk, suggesting TAVR as a better treatment approach (43, 44) . It is also likely, however, that many frail patients will not improve after TAVR. Interestingly, in the current study, several parameters found to be independent correlates for mortality in CLD patients undergoing TAVR are also considered as "frailty parameters," including poor patient mobility and low BMI. Low BMI is a well-recognized risk factor in the general population of CLD patients (32) . It is impossible to define clinical futility in a large population and each individual patient should be specifically evaluated. It appears, however, that many frail and immobile CLD patients do not gain significant improvement after TAVR. Clinical implications. The importance of a careful preoperative evaluation of CLD patients undergoing evaluation for TAVR cannot be overestimated (45, 46) . A heart-team discussion, which includes a pulmonologist, should balance the potential risks and benefits for the individual patient as well as the plan for perioperative management. The clinical manifestations of CLD and AS are occasionally similar (47) . Up-to-date lung function evaluation and laboratory B-type natriuretic peptide levels could assist in identifying symptom etiology (48) . For individual CLD patients with markers for poor outcome after TAVR, such as oxygen dependency or immobility, TAVR should be offered only after discussing the propensity for clinical benefit. Very high-risk lung disease patients, for whom symptom etiology is unclear, could be considered for balloon aortic valvuloplasty, for both temporary support and in order to test for symptom etiology (49, 50) . CLD patients who have clinically improved after valvuloplasty can be expected to have a sustained improvement after TAVR. When TAVR is considered in CLD patients, optimal respiratory status should be reached before the procedure. Short-term pulmonary rehabilitation and inspiratory muscle training could be offered to selected severe CLD patients before TAVR as well (46, 51) . Additionally, although data are lacking, performing TAVR with a "minimalist approach," using light sedation only, rather than general anesthesia, could be a superior therapeutic approach in lung disease patients (52, 53) . Study limitations. Although the PARTNER trial is a prospective, randomized trial, the current study is a posthoc subanalysis. Nevertheless, the comparisons of TAVR treatment versus control included CLD patients with very similar baseline characteristics, as shown in Table 1 . Additionally, the majority of TAVR procedures included in the PARTNER trial were performed under general anesthesia. CLD patients undergoing TAVR under conscious sedation may produce different clinical outcomes. Finally, the study was limited by a lack of data on the degree of patient airflow obstruction at baseline. Yet, all patients included in the PARTNER trial were presented and adjudicated during conference calls with the executive committee and other investigators. During these presentations, data on lung disease severity is commonly discussed and pulmonologists are usually part of the heart-team decision making. In addition, it should be noted that pulmonary function test interpretation is very limited in congestive heart failure patients (54) and mean FEV1 improves by up to 35% and may return to normal only by diuresis in these patients (55) . Moreover, a recently published paper revealed that pulmonary function tests commonly improve after aortic valve replacement surgery (56) . Interpretation of pulmonary function tests is even more challenging in frail, elderly patients, such as those included in the PARTNER trial (the majority are octogenarians). Furthermore, it has been found that the degree of airflow obstruction in CLD patients is not as effective a predictor for clinical outcome as are other parameters, such as patient mobility (32) .
Conclusions
Although CLD patients undergoing TAVR have worse outcomes than patients without CLD, TAVR is better in these patients than standard therapy and is similar to SAVR. Therefore, patients with combined severe AS and CLD should generally be considered for TAVR in a similar way to other high-risk patients. However, CLD patients who are either oxygen-dependent or have very limited mobility have poor outcomes after the procedure and performing TAVR in these cases may be futile.
